Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd at 4:30 p.m. ET.
The company currently markets two key products: HEPLISAV-B, an approved hepatitis B vaccine for adults in the US, EU, and UK, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (Nasdaq: DVAX), una società biofarmaceutica in fase commerciale focalizzata sullo sviluppo di vaccini innovativi, parteciperà a una fireside chat al Wells Fargo Healthcare Conference 2025 il 3 settembre alle 16:30 ET.
La società commercializza attualmente due prodotti principali: HEPLISAV-B, un vaccino approvato contro l'epatite B per gli adulti negli Stati Uniti, nell'UE e nel Regno Unito, e il CpG 1018 adjuvant, impiegato in HEPLISAV-B e in diversi vaccini contro il COVID-19.
Dynavax Technologies (Nasdaq: DVAX), una compañía biofarmacéutica en fase comercial centrada en el desarrollo de vacunas innovadoras, participará en una charla informal en el Wells Fargo Healthcare Conference 2025 el 3 de septiembre a las 4:30 p.m. ET.
La empresa comercializa actualmente dos productos clave: HEPLISAV-B, una vacuna contra la hepatitis B aprobada para adultos en EE. UU., la UE y el Reino Unido, y el adyuvante CpG 1018, utilizado en HEPLISAV-B y en diversas vacunas contra la COVID-19.
Dynavax Technologies (Nasdaq: DVAX), 혁신적인 백신 개발에 주력하는 상업 단계의 바이오제약사로서, 2025 Wells Fargo Healthcare Conference에서 9월 3일 오후 4시 30분(ET)에 파이어사이드 채팅에 참여합니다.
회사는 현재 두 가지 주요 제품을 판매하고 있습니다: HEPLISAV-B는 미국, EU 및 영국에서 성인용으로 승인된 B형간염 백신이며, CpG 1018 보조제는 HEPLISAV-B와 여러 COVID-19 백신에 사용됩니다.
Dynavax Technologies (Nasdaq: DVAX), une société biopharmaceutique en phase commerciale axée sur le développement de vaccins innovants, participera à une conversation informelle lors de la Wells Fargo Healthcare Conference 2025 le 3 septembre à 16h30 (ET).
L'entreprise commercialise actuellement deux produits clés : HEPLISAV-B, un vaccin contre l'hépatite B approuvé pour les adultes aux États-Unis, dans l'UE et au Royaume-Uni, et l'adjuvant CpG 1018, utilisé dans HEPLISAV-B et plusieurs vaccins contre la COVID-19.
Dynavax Technologies (Nasdaq: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Schwerpunkt auf der Entwicklung innovativer Impfstoffe, wird an einem Fireside-Chat auf der Wells Fargo Healthcare Conference 2025 am 3. September um 16:30 Uhr ET teilnehmen.
Das Unternehmen vertreibt derzeit zwei Hauptprodukte: HEPLISAV-B, einen für Erwachsene zugelassenen Hepatitis-B-Impfstoff in den USA, der EU und dem Vereinigten Königreich, sowie den CpG 1018 Adjuvans, der in HEPLISAV-B und in verschiedenen COVID-19-Impfstoffen verwendet wird.
- None.
- None.
The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-in-the-2025-wells-fargo-healthcare-conference-302540380.html
SOURCE Dynavax Technologies
FAQ
When is Dynavax (DVAX) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access Dynavax's Wells Fargo conference presentation?
What are Dynavax's (DVAX) main commercial products?
Where is HEPLISAV-B vaccine approved for use?
